Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy

Romiplostim can improve platelet counts in about 50% of patients with low‐ or intermediate 1‐risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but its long‐term toxicity and efficacy are not known. This open‐label extension study evaluated the long‐term safety and efficacy of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenaux, Pierre, Muus, Petra, Kantarjian, Hagop, Lyons, Roger M., Larson, Richard A., Sekeres, Mikkael A., Becker, Pamela S., Orejudos, Amelia, Franklin, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600084/
https://www.ncbi.nlm.nih.gov/pubmed/28616874
http://dx.doi.org/10.1111/bjh.14792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600084/
https://www.ncbi.nlm.nih.gov/pubmed/28616874
http://dx.doi.org/10.1111/bjh.14792

Ejemplares similares